《新生儿高氨血症诊断与治疗的专家共识》解读

蔡成; 赵武; 郝虎; 史源

doi:10.7499/j.issn.1008-8830.2409151

PDF(779 KB)

HTML

中国当代儿科杂志 ›› 2025, Vol. 27 ›› Issue (5) : 515-523. DOI: 10.7499/j.issn.1008-8830.2409151

指南解读

《新生儿高氨血症诊断与治疗的专家共识》解读

蔡成 ¹ ,
赵武 ² ,
郝虎 ³ ,
史源 ⁴

作者信息 +

Interpretation of the "Expert consensus on the diagnosis and treatment of neonatal hyperammonemia"

Cheng CAI ¹ ,
Wu ZHAO ² ,
Hu HAO ³ ,
Yuan SHI ⁴

Author information +

文章历史 +

摘要

该文对2023年5月《中国当代儿科杂志》发表的《新生儿高氨血症诊断与治疗的专家共识》进行解读，解读重点包括氨的神经毒性、病因分类、诊断、营养管理及药物治疗，旨在增强血氨检测意识，不能因等待病因检查而推迟治疗，以达到推动新生儿高氨血症诊断与治疗的目的。

Abstract

This paper provides an interpretation of the "Expert consensus on the diagnosis and treatment of neonatal hyperammonemia" published in the May 2023 issue of the Chinese Journal of Contemporary Pediatrics. The interpretation focuses on key aspects such as the neurotoxicity of ammonia, classification of etiologies, diagnosis, nutritional management, and pharmacological treatment. The aim is to enhance awareness about ammonia testing and emphasize that treatment should not be delayed while awaiting etiological investigation, thereby advancing the diagnosis and treatment of neonatal hyperammonemia.

导出引用

蔡成, 赵武, 郝虎, 等. 《新生儿高氨血症诊断与治疗的专家共识》解读[J]. 中国当代儿科杂志. 2025, 27(5): 515-523 https://doi.org/10.7499/j.issn.1008-8830.2409151

Cheng CAI, Wu ZHAO, Hu HAO, et al. Interpretation of the "Expert consensus on the diagnosis and treatment of neonatal hyperammonemia"[J]. Chinese Journal of Contemporary Pediatrics. 2025, 27(5): 515-523 https://doi.org/10.7499/j.issn.1008-8830.2409151

参考文献

列表( 原文顺序 | 文献年度倒序 | 文中引用次数倒序 ) 可视化分析

1	Ni B, Qin M, Zhao J, et al. A glance at transient hyperammonemia of the newborn: pathophysiology, diagnosis, and treatment: a review[J]. Medicine (Baltimore), 2022, 101(48): e31796. PMCID: PMC9726343. DOI: 10.1097/MD.0000000000031796 . https://www.ncbi.nlm.nih.gov/pubmed/36482558 本文引用 [39]

Raina

, Bedoyan

, Lichter-Konecki

, et al. Consensus guidelines for management of hyperammonaemia in paediatric patients receiving continuous kidney replacement therapy[J]. Nat Rev Nephrol, 2020, 16(8): 471-482. PMCID: PMC7366888. DOI: 10.1038/s41581-020-0267-8 .

https://www.ncbi.nlm.nih.gov/pubmed/32269302

本文引用 [19]

3	中华医学会儿科学分会新生儿学组青年委员会. 新生儿高氨血症诊断与治疗的专家共识[J].中国当代儿科杂志, 2023, 23(5): 437-447. DOI: 10.7499/j.issn.1008-8830.2302140 . 本文引用 [3]

4	Dasarathy S, Mookerjee RP, Rackayova V, et al. Ammonia toxicity: from head to toe?[J]. Metab Brain Dis, 2017, 32(2): 529-538. PMCID: PMC8839071. DOI: 10.1007/s11011-016-9938-3 . https://www.ncbi.nlm.nih.gov/pubmed/28012068 本文引用 [5]

5	Ribas GS, Lopes FF, Deon M, et al. Hyperammonemia in inherited metabolic diseases[J]. Cell Mol Neurobiol, 2022, 42(8): 2593-2610. DOI: 10.1007/s10571-021 -01156-6 . https://www.ncbi.nlm.nih.gov/pubmed/34665389 本文引用 [4]

6	Hediger N, Landolt MA, Diez-Fernandez C, et al. The impact of ammonia levels and dialysis on outcome in 202 patients with neonatal onset urea cycle disorders[J]. J Inherit Metab Dis, 2018, 41(4):689-698. DOI: 10.1007/s10545-018-0157-4 . https://www.ncbi.nlm.nih.gov/pubmed/29520739 本文引用 [7]

7	Ballard RA, Vinocur B, Reynolds JW, et al. Transient hyperammonemia of the preterm infant[J]. N Engl J Med, 1978, 299(17): 920-925. DOI: 10.1056/NEJM197810262991704 . https://www.ncbi.nlm.nih.gov/pubmed/692597 本文引用 [1]

8	Chapel-Crespo CC, Diaz GA, Oishi K. Efficacy of N-carbamoyl-L-glutamic acid for the treatment of inherited metabolic disorders[J]. Expert Rev Endocrinol Metab, 2016, 11(6): 467-473. PMCID: PMC6054484. DOI: 10.1080/17446651.2016.1239526 . https://www.ncbi.nlm.nih.gov/pubmed/30034506 本文引用 [3]

9	Md AN. Neonatal presentations of metabolic disorders[J]. Neoreviews, 2020, 21(10):e649-e662. DOI: 10.1542/neo.21-10-e649 . https://www.ncbi.nlm.nih.gov/pubmed/33004558 本文引用 [3]

10	Matoori S, Leroux JC. Recent advances in the treatment of hyperammonemia[J]. Adv Drug Deliv Rev, 2015, 90:55-68. DOI: 10.1016/j.addr.2015.04.009 . https://www.ncbi.nlm.nih.gov/pubmed/25895618 本文引用 [2]

11	Häberle J. Clinical and biochemical aspects of primary and secondary hyperammonemic disorders[J]. Arch Biochem Biophys, 2013, 536(2):101-108. DOI: 10.1016/j.abb.2013.04.009 . https://www.ncbi.nlm.nih.gov/pubmed/23628343 本文引用 [8]

12	Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision[J]. J Inherit Metab Dis, 2019, 42(6): 1192-1230. DOI: 10.1002/jimd.12100 . https://www.ncbi.nlm.nih.gov/pubmed/30982989 本文引用 [31]

Burlina

, Gasperini

, la Marca

, et al. Long-term management of patients with mild urea cycle disorders identified through the newborn screening: an expert opinion for clinical practice[J]. Nutrients, 2023, 16(1):13. PMCID: PMC10780676. DOI: 10.3390/nu16010013 .

https://www.ncbi.nlm.nih.gov/pubmed/38201843

本文引用 [3]

14	Summar ML, Mew NA. Inborn errors of metabolism with hyperammonemia: urea cycle defects and related disorders[J]. Pediatr Clin North Am, 2018, 65(2):231-246. DOI: 10.1016/j.pcl.2017.11.004 . https://www.ncbi.nlm.nih.gov/pubmed/29502911 本文引用 [3]

15	Guilder LL, Kronick JB. Organic acidemias[J]. Pediatr Rev, 2022, 43(3):123-134. DOI: 10.1542/pir.2020-000562 . https://www.ncbi.nlm.nih.gov/pubmed/35229111 本文引用 [3]

16	Häberle J, Chakrapani A, Ah Mew N, et al. Hyperammonaemia in classic organic acidaemias: a review of the literature and two case histories[J]. Orphanet J Rare Dis, 2018, 13(1): 219. PMCID: PMC6282273. DOI: 10.1186/s13023-018-0963-7 . https://www.ncbi.nlm.nih.gov/pubmed/30522498 本文引用 [3]

17	中华预防医学会出生缺陷预防与控制专业委员会新生儿筛查学组, 中华医学会儿科学分会临床营养学组, 中华医学会儿科学分会内分泌遗传代谢学组, 等. 单纯型甲基丙二酸尿症饮食治疗与营养管理专家共识[J]. 中国实用儿科杂志, 2018, 33(7): 481-486. DOI:10.19538/j.ek2018070601 . 本文引用 [1]

Chakrapani

, Valayannopoulos

, Segarra

, et al. Effect of carglumic acid with or without ammonia scavengers on hyperammonaemia in acute decompensation episodes of organic acidurias[J]. Orphanet J Rare Dis, 2018, 13(1):97. PMCID: PMC6011521. DOI: 10.1186/s13023-018-0840-4 .

https://www.ncbi.nlm.nih.gov/pubmed/29925411

本文引用 [2]

Valayannopoulos

, Baruteau

, Delgado

, et al. Carglumic acid enhances rapid ammonia detoxification in classical organic acidurias with a favourable risk-benefit profile: a retrospective observational study[J]. Orphanet J Rare Dis, 2016, 11: 32. PMCID: PMC4815113. DOI: 10.1186/s13023-016-0406-2 .

https://www.ncbi.nlm.nih.gov/pubmed/27030250

本文引用 [4]

Yap

, Lamireau

, Feillet

, et al. Real-world experience of carglumic acid for methylmalonic and propionic acidurias: an interim analysis of the multicentre observational PROTECT study[J]. Drugs R D, 2024, 24(1): 69-80. PMCID: PMC11035519. DOI: 10.1007/s40268-023-00449-z .

https://www.ncbi.nlm.nih.gov/pubmed/38198106

本文引用 [2]

21	Ali R, Nagalli S. Hyperammonemia[M]//StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2023. 本文引用 [1]

22	Moore K, Dixit D, Wagner M. Topiramate-related hyperammonemia[J]. J Pharm Technol, 2016, 32(1):34-36. PMCID: PMC5998406. DOI: 10.1177/8755122515605849 . https://www.ncbi.nlm.nih.gov/pubmed/34860953 本文引用 [1]

23	Savy N, Brossier D, Brunel-Guitton C, et al. Acute pediatric hyperammonemia: current diagnosis and management strategies[J]. Hepat Med, 2018, 10: 105-115. PMCID: PMC6140721. DOI: 10.2147/HMER.S140711 . https://www.ncbi.nlm.nih.gov/pubmed/30254497 本文引用 [5]

Bélanger-Quintana

, Arrieta Blanco

, Barrio-Carreras

, et al. Recommendations for the diagnosis and therapeutic management of hyperammonaemia in paediatric and adult patients[J]. Nutrients, 2022, 14(13):2755. PMCID: PMC9269083. DOI: 10.3390/nu14132755 .

https://www.ncbi.nlm.nih.gov/pubmed/35807935

本文引用 [2]

25	Forny P, Hörster F, Ballhausen D, et al. Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: first revision[J]. J Inherit Metab Dis, 2021, 44(3):566-592. PMCID: PMC8252715. DOI: 10.1002/jimd.12370 . https://www.ncbi.nlm.nih.gov/pubmed/33595124 本文引用 [1]

26	中华人民共和国国家卫生健康委员会. 国家卫生健康委办公厅关于印发罕见病诊疗指南（2019年版）的通知: 国卫办医函〔2019〕198号[EB/OL]. (2019-02-27)[2025-01-11]. http://www.nhc.gov.cn/yzygj/s7659/201902/61d06b4916c348e0810ce1fceb844333.shtml 本文引用 [2]

Longo

, Diaz

, Lichter-Konecki

, et al. Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders[J]. Mol Genet Metab, 2021, 132(1):19-26. PMCID: PMC8655853. DOI: 10.1016/j.ymgme.2020.12.002 .

https://www.ncbi.nlm.nih.gov/pubmed/33388234

本文引用 [4]

Berry

, Lichter-Konecki

, Diaz

, et al. Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes[J]. Mol Genet Metab, 2014, 112(1):17-24. PMCID: PMC4382922. DOI: 10.1016/j.ymgme.2014.02.007 .

https://www.ncbi.nlm.nih.gov/pubmed/24630270

本文引用 [2]

29	Diaz GA, Schulze A, Longo N, et al. Long-term safety and efficacy of glycerol phenylbutyrate for the management of urea cycle disorder patients[J]. Mol Genet Metab, 2019, 127(4): 336-345. DOI: 10.1016/j.ymgme.2019.07.004 . https://www.ncbi.nlm.nih.gov/pubmed/31326288 本文引用 [1]

30	Imbard A, Bouchereau J, Arnoux JB, et al. Citrulline in the management of patients with urea cycle disorders[J]. Orphanet J Rare Dis, 2023, 18(1): 207. PMCID: PMC10362745. DOI: 10.1186/s13023-023-02800-8 . https://www.ncbi.nlm.nih.gov/pubmed/37480106 本文引用 [1]

31	Vernon HJ, Manoli I. Milestones in treatments for inborn errors of metabolism: reflections on where chemistry and medicine meet[J]. Am J Med Genet A, 2021, 185(11):3350-3358. DOI: 10.1002/ajmg.a.62385 . https://www.ncbi.nlm.nih.gov/pubmed/34165242 本文引用 [1]

Burlina

, Bettocchi

, Biasucci

, et al. Long-term use of carglumic acid in methylmalonic aciduria, propionic aciduria and isovaleric aciduria in Italy: a qualitative survey[J]. Eur Rev Med Pharmacol Sci, 2022, 26(14): 5136-5143. DOI: 10.26355/eurrev_202207_29302 .

https://www.ncbi.nlm.nih.gov/pubmed/35916811

本文引用 [2]

33	Baumgartner MR, Hörster F, Dionisi-Vici C, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia[J]. Orphanet J Rare Dis, 2014, 9:130. PMCID: PMC4180313. DOI: 10.1186/s13023-014-0130-8 . https://www.ncbi.nlm.nih.gov/pubmed/25205257 本文引用 [1]

Ronco

, Garzotto

, Brendolan

, et al. Continuous renal replacement therapy in neonates and small infants: development and first-in-human use of a miniaturised machine (CARPEDIEM)[J]. Lancet, 2014, 383(9931):1807-1813. DOI: 10.1016/S0140-6736(14)60799-6 .

https://www.ncbi.nlm.nih.gov/pubmed/24856026

本文引用 [2]

35	Goldstein SL, Vidal E, Ricci Z, et al. Survival of infants treated with CKRT: comparing adapted adult platforms with the Carpediem™[J]. Pediatr Nephrol, 2022, 37(3): 667-675. PMCID: PMC8376293. DOI: 10.1007/s00467-021-05180-y . https://www.ncbi.nlm.nih.gov/pubmed/34414499 本文引用 [1]